CD19 and BTK Inhibitor Combination for Hematological Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B cell hematological malignancies and solid tumors are limited by the protective effects of the tumor microenvironment, and there is a need for more efficacious therapies that target both tumor cells and the supportive microenvironment.
Innovation Solution
The combination of a CD19 inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor, which can be administered alone or with an anti-CD20 antibody, to target B cell malignancies and solid tumors, disrupting signaling between tumor cells and the microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent therapy with CD19 inhibitor or BTK inhibitor is used, then treatment simplicity is maintained, but therapeutic efficacy is limited due to protective effects of tumor microenvironment
Solution Approach 1:
The patent combines CD19 inhibitor and BTK inhibitor into a single therapeutic regimen, creating a combination therapy that targets both tumor cells directly and the tumor microenvironment. This merging of two therapeutic agents works synergistically to overcome the protective effects of the microenvironment that limit single-agent therapies, thereby improving therapeutic efficacy despite increased treatment complexity
Solution Approach 2:
The combination therapy segments the anti-tumor approach into two distinct mechanisms: CD19 inhibition for direct tumor cell targeting and BTK inhibition for microenvironment modulation. This segmentation allows each agent to address specific aspects of tumor pathology independently while working together for enhanced overall efficacy
2Reliability
If combination therapy with CD19 inhibitor and BTK inhibitor is used, then therapeutic efficacy is enhanced by targeting both tumor cells and microenvironment, but treatment complexity increases
Solution Approach 1:
The patent merges CD19 inhibitor and BTK inhibitor into an integrated combination therapy regimen. This merging strategy addresses the technical contradiction by combining two mechanisms of action that target different aspects of the disease (tumor cells and microenvironment), achieving enhanced therapeutic efficacy while managing the inherent complexity through coordinated administration
Solution Approach 2:
The combination therapy acts as an intermediary system between the immune system and tumor microenvironment. By introducing both CD19 inhibitor and BTK inhibitor, the treatment mediates complex interactions to overcome immune suppression and enhance anti-tumor immunity, thereby improving efficacy despite increased treatment complexity
3Reliability
If CD19 inhibitor alone is administered, then immune response is activated against CD19+ cells, but immune suppression by microenvironment limits tumor clearance
Solution Approach 1:
The patent converts the harmful effect of immune suppression into a benefit by using BTK inhibitor to specifically target and disrupt the suppressive microenvironment. This allows the immune response activated by CD19 inhibitor to proceed more effectively, transforming the previously harmful suppressive conditions into a favorable environment for tumor clearance
Solution Approach 2:
The combination of CD19 inhibitor and BTK inhibitor merges direct tumor cell targeting with microenvironment modulation. This merging strategy simultaneously activates immune response against tumor cells while removing immune suppression barriers, thereby achieving enhanced tumor clearance efficiency that neither agent can achieve alone
Data Source
AI summary
Therapeutic combinations of a CD 19 inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a CD 19 inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer, such as a hematological malignancy. A combination of a BTK inhibitor and a CD 19 inhibitor, such as a CD19-targeted antibody or a CD19-targeted chimeric antigen receptor expressing T cell or NK cell, and compositions and uses thereof are disclosed. Combinations of a BTK inhibitor and a CD 19 inhibitor with a programmed death-1 (PD-1) or PD-1 ligand (PD-L1) inhibitor and compositions and uses thereof are also disclosed.